Good Life Advisors LLC Trims Holdings in BrainsWay Ltd. (NASDAQ:BWAY)

Good Life Advisors LLC decreased its holdings in BrainsWay Ltd. (NASDAQ:BWAYFree Report) by 7.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 35,720 shares of the company’s stock after selling 3,000 shares during the period. Good Life Advisors LLC owned about 0.21% of BrainsWay worth $231,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Worth Venture Partners LLC bought a new position in shares of BrainsWay during the 2nd quarter worth $721,000. Legato Capital Management LLC bought a new position in shares of BrainsWay during the 4th quarter worth $542,000. AIGH Capital Management LLC grew its position in shares of BrainsWay by 6.5% during the 3rd quarter. AIGH Capital Management LLC now owns 1,355,022 shares of the company’s stock worth $5,474,000 after buying an additional 83,262 shares in the last quarter. Wasatch Advisors Inc. grew its position in shares of BrainsWay by 4.7% during the 1st quarter. Wasatch Advisors Inc. now owns 1,285,631 shares of the company’s stock worth $11,198,000 after buying an additional 58,172 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of BrainsWay during the 1st quarter worth $55,000. Hedge funds and other institutional investors own 30.11% of the company’s stock.

BrainsWay Price Performance

Shares of BWAY stock opened at $5.29 on Friday. BrainsWay Ltd. has a 1-year low of $1.38 and a 1-year high of $7.61. The stock’s 50-day moving average is $6.09 and its 200 day moving average is $5.42. The company has a market cap of $88.03 million, a P/E ratio of -40.69 and a beta of 1.22.

BrainsWay (NASDAQ:BWAYGet Free Report) last issued its quarterly earnings data on Wednesday, March 6th. The company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. BrainsWay had a negative return on equity of 10.05% and a negative net margin of 13.20%. The company had revenue of $9.03 million for the quarter, compared to the consensus estimate of $8.40 million. During the same quarter last year, the company earned ($0.12) earnings per share. On average, analysts anticipate that BrainsWay Ltd. will post -0.02 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating on shares of BrainsWay in a research report on Monday, March 11th.

View Our Latest Stock Report on BrainsWay

About BrainsWay

(Free Report)

Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, the Asia Pacific, Europe, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.

Read More

Want to see what other hedge funds are holding BWAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BrainsWay Ltd. (NASDAQ:BWAYFree Report).

Institutional Ownership by Quarter for BrainsWay (NASDAQ:BWAY)

Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.